balsalazide disodium (Colazal) vs mesalamine (Asacol HD)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline

balsalazide disodium (Colazal)

Rights held by Bausch Health; US product discontinued

Approved in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

mesalamine (Asacol HD)

Rights held by AbbVie

US approval withdrawn in Ulcerative Colitissmall molecule
Partial signal

NCT00577473 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 301 participants, comparing mesalamine 4.8 g/day with mesalamine 2.4 g/day. The primary clinical and sigmoidoscopy-based treatment-success endpoint was not significantly different between doses (p=0.4411), so the results provide well-controlled but inconclusive evidence that the higher dose is more effective.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbalsalazide disodium (Colazal)mesalamine (Asacol HD)
Clinical remission (induction)—Not reported—Not posted · NCT00548574
Clinical remission (maintenance)—Not reported—Not posted · NCT00548574
Clinical response (induction)—Not reported—Not posted · NCT00548574
Endoscopic improvement (induction)—Not reported—Not posted · NCT00548574
Corticosteroid-free remission (maintenance)—Not reported—Not posted · NCT00548574

Clinical remission (induction)

balsalazide disodium (Colazal)
—Not reported
mesalamine (Asacol HD)
—Not posted · NCT00548574

Clinical remission (maintenance)

balsalazide disodium (Colazal)
—Not reported
mesalamine (Asacol HD)
—Not posted · NCT00548574

Clinical response (induction)

balsalazide disodium (Colazal)
—Not reported
mesalamine (Asacol HD)
—Not posted · NCT00548574

Endoscopic improvement (induction)

balsalazide disodium (Colazal)
—Not reported
mesalamine (Asacol HD)
—Not posted · NCT00548574

Corticosteroid-free remission (maintenance)

balsalazide disodium (Colazal)
—Not reported
mesalamine (Asacol HD)
—Not posted · NCT00548574
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

balsalazide disodium (Colazal): no structured comparison results are available for Ulcerative Colitis.

mesalamine (Asacol HD): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: balsalazide disodium (Colazal)'s landscape · mesalamine (Asacol HD)'s landscape